DK2170831T3 - Benzazepin-derivater egnede som vasopressin-antagonister - Google Patents

Benzazepin-derivater egnede som vasopressin-antagonister

Info

Publication number
DK2170831T3
DK2170831T3 DK08765871.2T DK08765871T DK2170831T3 DK 2170831 T3 DK2170831 T3 DK 2170831T3 DK 08765871 T DK08765871 T DK 08765871T DK 2170831 T3 DK2170831 T3 DK 2170831T3
Authority
DK
Denmark
Prior art keywords
derivatives useful
vasopressin antagonists
benzazepine derivatives
benzazepine
vasopressin
Prior art date
Application number
DK08765871.2T
Other languages
Danish (da)
English (en)
Inventor
Kazumi Kondo
Yasuhiro Menjo
Takahiro Tomoyasu
Shin Miyamura
Yuso Tomohira
Takakuni Matsuda
Keigo Yamada
Yusuke Kato
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK2170831T3 publication Critical patent/DK2170831T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08765871.2T 2007-06-26 2008-06-26 Benzazepin-derivater egnede som vasopressin-antagonister DK2170831T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007167207 2007-06-26
PCT/JP2008/062033 WO2009001968A1 (en) 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists

Publications (1)

Publication Number Publication Date
DK2170831T3 true DK2170831T3 (da) 2012-05-21

Family

ID=39773045

Family Applications (3)

Application Number Title Priority Date Filing Date
DK08765871.2T DK2170831T3 (da) 2007-06-26 2008-06-26 Benzazepin-derivater egnede som vasopressin-antagonister
DK11172828.3T DK2374797T3 (da) 2007-06-26 2008-06-26 Benzazepinderivater til anvendelse som vasopressinantagonister
DK11172829.1T DK2374798T3 (da) 2007-06-26 2008-06-26 Benzazepin-derivat til anvendelse som vasopressin-antagonister

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK11172828.3T DK2374797T3 (da) 2007-06-26 2008-06-26 Benzazepinderivater til anvendelse som vasopressinantagonister
DK11172829.1T DK2374798T3 (da) 2007-06-26 2008-06-26 Benzazepin-derivat til anvendelse som vasopressin-antagonister

Country Status (27)

Country Link
US (3) US8669229B2 (OSRAM)
EP (3) EP2170831B1 (OSRAM)
JP (3) JP5653043B2 (OSRAM)
KR (1) KR101487201B1 (OSRAM)
CN (3) CN103342679A (OSRAM)
AR (1) AR067176A1 (OSRAM)
AT (1) ATE545633T1 (OSRAM)
AU (1) AU2008269918B2 (OSRAM)
BR (1) BRPI0813768A2 (OSRAM)
CA (1) CA2690335A1 (OSRAM)
CO (1) CO6160295A2 (OSRAM)
CY (3) CY1113519T1 (OSRAM)
DK (3) DK2170831T3 (OSRAM)
ES (3) ES2380085T3 (OSRAM)
HR (3) HRP20120310T1 (OSRAM)
IL (1) IL202561A0 (OSRAM)
MY (3) MY148312A (OSRAM)
NZ (3) NZ581723A (OSRAM)
PH (2) PH12012501363A1 (OSRAM)
PL (3) PL2170831T3 (OSRAM)
PT (3) PT2170831E (OSRAM)
RU (1) RU2471784C2 (OSRAM)
SG (2) SG182230A1 (OSRAM)
SI (3) SI2374797T1 (OSRAM)
TW (1) TWI459947B (OSRAM)
UA (1) UA98966C2 (OSRAM)
WO (1) WO2009001968A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
JP5656399B2 (ja) * 2008-12-26 2015-01-21 大塚製薬株式会社 医薬及び医薬製剤
CN102030709B (zh) * 2009-09-25 2013-10-16 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
EA022253B1 (ru) * 2009-10-26 2015-11-30 Оцука Фармасьютикал Ко., Лтд. Соединение бензазепина и его применения
GB201105537D0 (en) 2011-03-31 2011-05-18 Vantia Ltd New process
CN102260213B (zh) * 2011-05-31 2013-05-15 重庆福安药业(集团)股份有限公司 一种托伐普坦的制备方法
TWI704919B (zh) * 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
CA2894516A1 (en) 2012-12-28 2014-07-03 Otsuka Pharmaceutical Co., Ltd. Injectable depot formulation comprising optically active tolvaptan and process of producing the same
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
TWI660748B (zh) * 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
WO2019003433A1 (ja) * 2017-06-30 2019-01-03 大塚製薬株式会社 ベンゾアゼピン誘導体
CN107540672A (zh) * 2017-10-10 2018-01-05 牡丹江医学院 一种治疗肝硬化的药物及其合成方法
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途
TW202246216A (zh) 2021-02-10 2022-12-01 大陸商上海森輝醫藥有限公司 苯并氮雜環庚烯類化合物及其製備方法和醫藥用途
CN113112528A (zh) * 2021-04-26 2021-07-13 中南财经政法大学 异常行为监控方法、装置、设备及存储介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045478A (en) * 1986-03-03 1991-09-03 Becton Dickinson And Company Vesicles and use thereof in an assay
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
CA2116334A1 (en) 1992-07-02 1994-01-20 Hidenori Ogawa Oxytocin antagonist
TW270927B (OSRAM) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
GB9726695D0 (en) 1997-12-17 1998-02-18 Smithkline Beecham Plc Novel compounds
JP4210355B2 (ja) 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
CN1165532C (zh) 1998-09-29 2004-09-08 惠氏控股有限公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
US6642270B2 (en) * 2000-05-15 2003-11-04 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
CN101374539A (zh) * 2004-11-02 2009-02-25 夏尔有限责任公司 改善肝脏递送的利巴韦林前药
ES2533007T3 (es) * 2005-12-27 2015-04-06 Otsuka Pharmaceutical Co., Ltd. Compuesto de benzoacepina soluble en agua y su composición farmacéutica
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑

Also Published As

Publication number Publication date
HRP20131095T1 (hr) 2014-01-03
HRP20120310T1 (hr) 2012-06-30
JP2010531293A (ja) 2010-09-24
PT2374797E (pt) 2014-05-02
AR067176A1 (es) 2009-09-30
HK1163660A1 (en) 2012-09-14
WO2009001968A1 (en) 2008-12-31
MY152805A (en) 2014-11-28
EP2374798A1 (en) 2011-10-12
US20140024640A1 (en) 2014-01-23
CA2690335A1 (en) 2008-12-31
JP5653043B2 (ja) 2015-01-14
EP2374797B1 (en) 2014-03-26
HK1141994A1 (en) 2010-11-26
BRPI0813768A2 (pt) 2014-12-30
JP5689195B2 (ja) 2015-03-25
PL2374798T3 (pl) 2014-01-31
SG182231A1 (en) 2012-07-30
EP2170831B1 (en) 2012-02-15
NZ581723A (en) 2012-03-30
IL202561A0 (en) 2010-06-30
US20140024619A1 (en) 2014-01-23
JP5893085B2 (ja) 2016-03-23
DK2374797T3 (da) 2014-05-12
PT2170831E (pt) 2012-04-13
EP2374797A1 (en) 2011-10-12
SI2374797T1 (sl) 2014-05-30
JP2014208680A (ja) 2014-11-06
EP2374798B1 (en) 2013-09-04
NZ598067A (en) 2012-12-21
ES2431515T3 (es) 2013-11-26
TW200911271A (en) 2009-03-16
ES2460018T3 (es) 2014-05-13
NZ598064A (en) 2013-04-26
SG182230A1 (en) 2012-07-30
DK2374798T3 (da) 2013-10-07
AU2008269918B2 (en) 2012-12-06
KR101487201B1 (ko) 2015-01-28
CN103342680A (zh) 2013-10-09
US8785386B2 (en) 2014-07-22
ATE545633T1 (de) 2012-03-15
CY1113519T1 (el) 2016-06-22
ES2380085T3 (es) 2012-05-08
CY1114491T1 (el) 2016-10-05
PT2374798E (pt) 2013-11-05
PL2374797T3 (pl) 2014-08-29
CO6160295A2 (es) 2010-05-20
TWI459947B (zh) 2014-11-11
PH12012501362A1 (en) 2014-04-28
HK1163077A1 (en) 2012-09-07
UA98966C2 (ru) 2012-07-10
CN101687805A (zh) 2010-03-31
EP2170831A1 (en) 2010-04-07
US20110071084A1 (en) 2011-03-24
RU2471784C2 (ru) 2013-01-10
SI2374798T1 (sl) 2013-10-30
MY148312A (en) 2013-03-29
RU2010102229A (ru) 2011-08-10
AU2008269918A1 (en) 2008-12-31
MY150941A (en) 2014-03-14
KR20100040873A (ko) 2010-04-21
US9073868B2 (en) 2015-07-07
CN103342679A (zh) 2013-10-09
CY1115226T1 (el) 2017-01-04
JP2014205703A (ja) 2014-10-30
PL2170831T3 (pl) 2012-08-31
SI2170831T1 (sl) 2012-04-30
PH12012501363A1 (en) 2014-04-28
US8669229B2 (en) 2014-03-11
HRP20140501T1 (hr) 2014-07-04

Similar Documents

Publication Publication Date Title
DK2170831T3 (da) Benzazepin-derivater egnede som vasopressin-antagonister
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
HRP20151108T1 (xx) Antagonisti nogo-receptora
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
BRPI0806499A2 (pt) Dispensador de aerossol com travamento
IL198345A0 (en) New sulfonamide derivatives as bradykinin antagonists
ATE501940T1 (de) Behälteranordnung
ATE480545T1 (de) Imidazo-verbindungen
DK2070834T3 (da) Hætteglasindretning
DK2089367T3 (da) Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
BRPI0810926A2 (pt) Antagonista de crig
IL197585A0 (en) New benzamide derivatives as bradykinin antagonists
DK1841758T3 (da) Substituerede triazol-derivater som oxytocin-antagonister
DK2205569T3 (da) Alkylthiopyrimidiner som crth2-antagonister
DK2342182T3 (da) Isoquinolinonderivater som nk3-antagonister
HU0600809D0 (en) New phenylsulfamoil benzamide derivatives as bradykinin antagonists
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
ZA200802339B (en) Indol-3-yl-carbonyl-azaspiro derivatives as vasopressin receptor antagonists
UY3648Q (es) Dispensador
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
ATE524972T1 (de) Poly-tlr-antagonist
FI20065536L (fi) Lukitusjärjestely
DK2456765T3 (da) Imidazolderivater som mglur5-antagonister
FI20065808L (fi) Lukitusjärjestely